Most women requiring continued cervical cancer screening — including those at high risk — do not continue screening after 65 years of age.

Cotesting, the practice of adding cytology to human papillomavirus (HPV) screening, offered little added benefit over HPV testing alone in the detection of precancer among women aged 25-65 years, ...

In 2026, cervical cancer remains a stark reminder of global health inequity, with women in low-income countries and lower-middle-income countries (LMICs) with a disproportionate share of the disease ...